A randomized controlled trial of Anamorelin to prevent weight loss in post-pancreaticoduodenectomy patients

Baba Taisuke0 个研究点目标入组 60 人开始时间: 2024年2月1日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1) Patients who underwent pancreatoduodenectomy for pancreatic cancer, have started oral intake by the 7th postoperative day, and have been judged by physician examination and x-ray photos to have an acceptable increase in food intake after starting anamorelin oral administration.
•2) Patients who have understood and agreed the concept of the study.
•3) Age more than 18, regardless of gender, preoperative complications, or stage of cancer.

•1) Patients who underwent laparoscopic/robotic-assisted surgery, or who have been diagnosed with benign disease/precancerous lesions
•2) Patients with benign/Premalignant lesions.
•3) Patients allergic to anamorelin
•4) Patients with contraindications to anamorelin (congestive heart failure, myocardial infarction/angina pectoris, severe stimulatory conduction system disorders, hepatic dysfunction (Child-Pugh class B and C), concomitant contraindication: clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir-containing products, cobicistat-containing products
•5) Patients who are not eligible for the study by the investigators decision.

发起方

Baba Taisuke